Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists
Authors:
- 28 February 2024
- journal article
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 71 (4) , 149-151
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- From NAFLD to MASLD: Promise and pitfalls of a new definitionJournal of Hepatology, 2023
- Lifestyle interventions in nonalcoholic fatty liver diseaseNature Reviews Gastroenterology & Hepatology, 2023
- Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology ClinicsEndocrine Practice, 2023
- Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United StatesMetabolism, 2023
- A global research priority agenda to advance public health responses to fatty liver diseaseJournal of Hepatology, 2023
- The Global Burden of Liver DiseaseClinical Gastroenterology and Hepatology, 2023
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical SettingsEndocrine Practice, 2022
- Poor Awareness of Liver Disease Among Adults With NAFLD in the United StatesHepatology Communications, 2021
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategiesThe Lancet Diabetes & Endocrinology, 2019
- Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínicaGastroenterología y Hepatología, 2018